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Background: Depressive disorders in childhood and adolescence are a major health 
problem and often follow a chronic course with severe consequences in later life. 
Depressive disorders cause the highest burden of disease in this age group across 
all medical conditions. Treatment adherence is usually very poor, and the use of 
antidepressant drugs is heavily debated, as suicidal ideations may increase, in particular 
in the early phase of treatment. Omega-3 fatty acids rich in eicosapentaenoic acid have 
shown some promising results in over a dozen small scale randomized controlled trials 
(RCTs) in adult major depressive disorders, with only very few published RCTs in children 
and adolescents. High-quality phase III RCTs are missing.
Methods and Design: The omega-3-pMDD trial is a carefully designed phase III RCT 
to assess the efficacy and safety of omega-3 fatty acids in the early course of pediatric 
major depressive disorder (MDD). The study is designed as a multi-center, double-
blinded, placebo-controlled, randomized clinical trial enrolling 220 patients aged 8 to 
17 years meeting DSM-IV criteria for major depressive disorder of at least moderate 
symptom severity. After a single-blinded placebo-lead-in phase (7 to 10 days) patients are 
randomly assigned to omega-3 fatty acids or placebo over 36 weeks. Primary outcomes 
are changes in depression severity, as well as remission and recovery rates. Secondary 
outcome measures include the omega-3 index and inflammatory parameters as predictors 
of response. Data analysis will be performed in the intention-to-treat sample using a 
(generalized) linear random intercept regression model. Through sampling of blood, hair, 
saliva, and urine, further putative biological markers for depression and omega-3 fatty 
response will be investigated.
Discussion: This trial addresses if omega-3 fatty acids play a role in the pathogenesis of 
pediatric MDDs and have antidepressant properties, in particular in clinically depressed 
children and adolescents with a pre-existing omega-3 fatty acid deficiency, increased 
markers of oxidative stress, and/or markers of (low grade) inflammation.
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INTRODuCTION
Prevalence rates of major depressive disorders (MDDs) are low 
in prepubertal children, but increase substantially throughout 
adolescence. In a recent representative survey of over 10,000 
adolescents aged 13 to 18 years, lifetime and 12-month 
prevalence were estimated at 11.0% and 7.5%, respectively (1). 
Females have a three times higher risk than males to undergo 
a first depressive episode between the ages of 12 and 17 years 
(2). About 20% of childhood-onset MDD will recover within 3 
months and about 60% within 9 months, which puts the mean 
length of childhood onset MDD to about 9 months (3). A more 
recent survey estimated the mean duration of an episode to 
be about 27 weeks (1), but with high individual variability (4). 
An early onset of the disease is a risk factor for chronic and 
recurrent forms of depression in adulthood with more than 
half experiencing a first relapse within five years (5). MDD is 
associated with difficulties in relationships, impaired school and 
work functioning, conduct problems, and an increased risk of 
substance abuse (2, 6, 7). Additionally, depressive disorders are 
major contributors to the burden of suicide and poor long-term 
health later in life (8, 9).
Depressive disorders are often not recognized by professionals 
(10) and only about a quarter receive appropriate treatment (11). 
These findings are alarming given that MDD is the leading cause 
of disability between 10 and 24 year olds (12).
Omega-3 Fatty Acids and Depression
The dramatic change in human life style, in particular in dietary 
habits, might be one of the reasons for the raise of civilization 
diseases, such as obesity, cardiovascular diseases, cancer, 
inflammatory, and autoimmune diseases, but also mental 
disorders such as depression, given that in modern societies 
the nutritional environment does not match the human genetic 
constitution (13). The modern Western dietary habits have 
changed in an unprecedented way since the industrial revolution 
with a dramatic shift from a balanced omega-3 to omega-6 ratio 
towards an excessive intake of omega-6 fatty acids. Nowadays, 
there are hardly any processed foods without an excess of 
omega-6 fatty acids due to the widespread industrial use of 
vegetable oils (e.g. sunflower oil). Furthermore, the intake of fish 
and other sources of omega-3 long chained polyunsaturated fatty 
acids (LC-PUFAs) have decreased, in particular in urban areas.
Epidemiological studies provide some evidence that high 
intake of fish seems to be a protective factor against the 
development of MDD (14), in particular in females (15). Case-
control studies confirm that a high fish intake reduces the relative 
risk for child and adolescent depression (16). Reduced levels 
of omega-3 fatty acids in red blood cells of depressed patients 
provide further evidence supporting a link between altered 
PUFA metabolism and depression (17). Interestingly, such a 
reduction in PUFAs is only found in patients experiencing a 
current depressive episode, but not in remitted patients (18, 19), 
suggesting a direct and reversible relationship between omega-3 
fatty acids deficiency and depression.
Meta analyses summarizing the results of various randomized 
placebo-controlled clinical trials on the efficacy of omega-3 
fatty acids treatment in MDD reported standardized mean 
differences ranging from 0.11 to 0.56 (an overview of all RCTs 
is given in SI Table 1), reaching different conclusions of the 
clinical significance of omega-3 fatty acids as an antidepressant 
(AD) treatment (20–30). A recent rigorous Cochrane review 
encompassing 20 RCTs in MDD suggests a small-to-modest 
benefit for depressive symptomology with an SMD = −0.32 
(27). Some of the inconsistencies between studies may also be 
explained by methodological differences, such as the inclusion/
exclusion criteria, study subgroup selection, and choice of drug 
composition. For example, omega-3 fatty acids have only been 
found to be effective in populations with a clinical diagnosis 
of depression, but not in subclinical depressed individuals 
(23, 28). In addition, formulations rich in eicosapentaenoic 
acid (EPA) seem to be more effective than formulations rich 
in docosahexaenoic acid (DHA) (26), although it is unclear 
whether the effects depend on a specific ratio of EPA to DHA (24) 
or solely on a higher EPA dose irrespective of the DHA content 
(28, 29). Furthermore, omega-3 fatty acids might be especially 
effective in depressed patients with no comorbid disorders 
(30), and some studies have shown that it is also effective as an 
augmentation to another AD therapy, possibly even more so 
(28, 29, 31). Nearly all meta-analyses come to the conclusion 
that, at present, we do not have sufficient evidence to support 
or rule out that omega-3 PUFAs are potential treatments for 
MDD or could reduce dosages of selective serotonin reuptake 
inhibitors (SSRI) medication in MDD. Adequately powered 
RCTs are, therefore, warranted.
Evidence in Children and Adolescents
In contrast to the abundance of studies conducted in adults, the 
evidence of a link between omega-3 fatty acids and depression in 
children and adolescents is relatively sparse. In a Japanese study 
including 6,700 adolescents aged 12 to 15 years daily fish intake 
was inversely associated with depressive symptoms, but only in 
college boys and not girls (16). Red blood cell fatty acid levels 
have also been shown to be lower in depressed adolescents than 
in healthy controls (32) although the highest effects were found 
in other fatty acids than EPA or DHA.
November 2019 | Volume 10 | Article 863Frontiers in Psychiatry | www.frontiersin.org
The Omega-3-pMDD Trial: Rationale and DesignHäberling et al.
3
The few randomized controlled trials conducted in minors 
showed at least partly encouraging results (see SI Table 1). In a 
small study including 20 depressed children aged 6 to 12 years, 
omega-3 fatty acid supplementation showed a large advantage 
over placebo (33). Given the small sample size, though, these 
results need to be interpreted with caution. Similarly, an RCT 
including 23 young adults around 20 years of age also showed 
significant reduction in depression severity after 3 weeks of 
omega-3 fatty acids treatment (34). In another small scale study 
including 35 patients with half of them getting a daily dose of 
2,400 mg omega-3 fatty acids and the other half getting the 
same amount of omega-6 fatty acids (35), a significant treatment 
effect was found for patients with a major depressive disorder. 
Patients with a mixed anxiety depressive disorder, however, did 
not benefit from the omega-3 fatty acid treatment. The largest 
study to date included 72 youth with pediatric depression 
aged 7 to 14 years which underwent omega-3 monotherapy, 
individual-family psychoeducational psychotherapy (PEP) or 
combinations, respectively, for a trial duration of 12 weeks (36). 
Omega-3 treatment showed a small to medium effect compared 
to placebo. In an interesting study including 14 adolescents with 
SSRI resistant MDD, half of the patients received a very high 
dose of 16.2 g omega-3 fatty acids per day and the other half a 
low dose of 2.4 g per day over 10 weeks (37). In the high-dose 
group, 100% of patients showed symptoms remissions compared 
to 40% in the low dose group. In contrast though, no beneficial 
effects of omega-3 fatty acids were found in an RCT including 51 
adolescents with MDD who were treated for a period of 10 weeks 
(38). In summary, preliminary data point towards beneficial 
effects of omega-3 fatty acids on pediatric depression but large-
scale studies are needed to validate these results.
Omega-3 Fatty Acids, Depression, and 
Cognition
Cognitive deficits are often observed in depressed individuals 
reflected in reduced concentration, attention, and impairments 
in executive and memory functions, among others (39). Even 
more so, residual cognitive deficits may persist after remission of 
the depressive episode affecting academic performance (40). The 
role of omega 3 fatty acids in improving cognitive functions has 
been extensively studied in a variety of populations ranging from 
infants to the elderly, and from healthy individuals to patients 
with psychiatric, neurodegenerative or neurodevelopment 
disorders. For example, omega 3 fatty acids supplementation has 
been shown to improve depressive symptoms and verbal fluency 
in elderly with mild cognitive impairments (41), although the 
effects might depend also on genetic variations of the patients 
(42). However, other studies reported no or only small beneficial 
effects (43, 44), or only on specific cognitive subdomains such as 
reaction time (45).
The evidence of a beneficial effect of omega-3 fatty acids on 
cognition in children and adolescents remains inconclusive. 
In a Danish study assessing the impact of a healthy diet on 
school performance in third and fourth grade children, the 
dietary intervention improved school performance and reading 
comprehension. Post hoc analysis revealed that about 20% of the 
intervention effect might be attributed to an increase in EPA and 
DHA levels due to the intake of fish (46). Similarly, end-term 
grades and vocabulary were found to be higher in the group of 
700 Dutch high school students who met the national guidelines 
of fish consumption compared to the group who never ate fish 
(47). In healthy adolescents aged 13 to 15 years, the blood level 
ratio between omega-3 and omega-6 correlated with scores on 
the letter Digit Substitution Test, indicating a higher information 
processing speed (48).
A recent meta-analysis confirmed a beneficial effect of 
omega-3 fatty acids in infants up to 18 months of age but not 
in children or adults (49), although the inclusion of a wide 
range of assessment instruments and age stages might raise 
questions regarding the validity of the result (50). Even if 
omega-3 fatty acids might not improve cognition in healthy 
developing children, they might alleviate cognitive deficits in 
adolescents with psychiatric disorders. For example, omega-3 
fatty acid supplementation for 16 weeks improved working 
memory but no other cognitive functions in children diagnosed 
with attention-deficit/hyperactivity disorder (ADHD) (51). 
Similarly, the level of DHA was lower in ADHD children with 
learning difficulties than in those without, and higher DHA 
levels predicted better word reading skills (52). In a recent meta-
analysis Chang and colleagues (53) concluded that omega-3 
fatty acids supplementation improves cognitive functioning 
associated with attention in ADHD children. Surprisingly, only 
one study to date assessed directly whether omega-3 fatty acid 
supplementation will not only improve mood symptoms in 
pediatric depression but also associated cognitive deficits. Vesco 
and colleagues (54) found improved executive functioning after 
a 12-week omega-3 fatty acid intervention. It remains to be 
established whether omega-3 fatty acids have beneficial effects 
on other cognitive domains that are often affected in pediatric 
depression, such as working memory or attention. Given the 
high prevalence of cognitive deficits in depressed youth and 
their impact on academic performance and school work, more 
studies using a set of different cognitive tests are necessary to 
evaluate differential effects of omega-3 fatty acids on cognitive 
functioning in depressed children and youth.
Biological Mechanism
Preclinical and clinical data point toward several mechanisms 
that most likely act in concert (55). For example, omega-3 
fatty acids have shown to attenuate the exaggerated, persistent 
elevation of the stress response in animal models with depressive 
features (56–58) and humans (59, 60). Several lines of evidence 
support an altered immune-modulation in the pathophysiology 
of depression. Inflammatory mediators, like cytokines, play 
an important role in the stress system by influencing the 
activity of the hypothalamic pituitary adrenal (HPA) axis (61). 
Chronic stress, elicits a neuroinflammatory response, releasing 
inflammatory mediators, such as interleukin-1β (IL-1β) and 
tumor necrosis factor-α (TNF-α) (62), two cytokines that are 
inhibited by omega-3 fatty acids. Chronic stress also alters 
activation of the immune system in the periphery, which might 
account for the state of chronic inflammation observed in 
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depressed patients (63). Omega-6 fatty acids such as arachidonic 
acid (AA) and omega-3 fatty acids such as EPA and DHA are both 
converted in bioactive molecules, also called eicosanoids. The 
eicosanoids derived from omega-3 and omega-6 fatty acids have 
partially opposing functions, with the first ones being mainly 
pro-inflammatory and the latter ones acting anti-inflammatory 
(64, 65). Both compete with each other for incorporation into 
cell membrane phospholipids (66–68). Omega-3 fatty acids 
inhibit the release of pro-inflammatory cytokines, such as IL-1β, 
IL-2, IL-6, interferon-γ, and TNFα (69). Given the link between 
depression and an increased production of pro-inflammatory 
cytokines (70), this inhibition might explain some of the AD 
effects of omega-3 fatty acids. Furthermore, cytokines also lower 
neurotransmitter precursor availability, and neurotransmitter 
metabolism (71), which might be important in the pathogenesis 
of mood disorders.
Omega-3 fatty acids are also crucially important for brain 
development. Myelination and synaptic pruning are core 
processes during normal pubertal brain development (72). The 
regulation of PUFA metabolism is crucial for both processes 
(73, 74). Of particular interest is a preclinical study investigating 
cognition and behavior across different developmental stages 
in rats. Omega-3 fatty acids deficient diets across consecutive 
generations produced a modality-selective and task-dependent 
impairment in cognitive and motivated behavior in adolescent 
rats distinct from the deficits observed in adult rats (75, 76). 
Omega-3 fatty acids supplementation was able to attenuate 
such depression-like animal behaviors during critical periods 
of brain development (77). Furthermore, omega-3 fatty acids 
have a preventive and neurotrophic effect against structural 
hippocampal alterations in animal models with depression- and 
anxiety-like behaviors (78–81). In addition, supplementation with 
omega-3 fatty acids might increase synaptic plasticity through an 
increase of brain-derived neurotrophic factor (BDNF), acting 
neuroprotective (71). Omega-3 fatty acids might ameliorate 
symptoms of depression through the protection of cells and their 
positive effects on neurogenesis, and counteract the shrinkage 
of the hippocampus (82). Omega-3 fatty acids deprived rats also 
provide evidence for an increase in serotonin 2 (5-HT2) and 
a decrease in dopamine 2 (D2) receptor density in the frontal 
cortex, as well as an increased serotonin turnover in the prefrontal 
cortex and decreased midbrain tryptophan hydroxylase-2 
expression (83–89). In humans, omega-3 intake is associated with 
an increase in cerebrospinal fluid 5-5-hydroxyindoleacetic acid 
(5-HIAA) release (90, 91).
Omega-3 fatty acids are essential components of intracellular 
und neuronal cell membranes, affecting cell membrane integrity 
and fluidity (69, 92, 93). Through their effect on the efficiency 
of membrane functioning, omega-3 fatty acids play a role in a 
variety of biological mechanisms, such as enzyme and receptor 
activity, ion channels functioning, and the production and 
activity of neurotransmitters (85, 94). An increase in membrane 
fluidity results in a more flexible membrane and facilitates 
transmission (95).
While supplementation of omega-3 fatty aims to increase 
concentrations of fatty acids and their derived bioactive lipids 
that are available to the organism, omega-3 fatty acid metabolism 
depends on a variety of factors, including genetic variations. 
Therefore, omega-3 fatty concentrations will be monitored over 
the course of the study with blood sampling procedures carried 
out at baseline, after 3 months, and at the end of the study. 
Remaining blood is stored in a biobank allowing for further 
analyses of various parameters associated with omega-3 fatty acid 
balance and depression as well as the impact of genetic makeups 
on fatty acid metabolism.
The Omega-3-pMDD Trial: Rationale
As summarized above, there is growing evidence for the efficacy 
of omega-3 fatty acids as a treatment for major depression, in 
particular in pediatric populations. The generalizability of the 
results, though, is hampered by the conduction of small-scale 
studies, which do not allow for an accurate estimation of effect 
sizes. Therefore, the implementation of a well-designed large-
scale clinical trial is warranted.
The present omega-3-pMDD trial recruits 220 patients with 
clinically diagnosed pediatric depression to assess the efficacy 
and safety of omega-3 fatty acids treatment. Given the knowledge 
gained from trials conducted in adults, formula rich in EPA will be 
used. In addition, comorbid disorders are assessed systematically 
for each patient, and concomitant medication is recorded 
throughout the 36-week trial. In case no concomitant medication 
is given, the efficacy of omega-3 fatty acid supplementation as a 
first line treatment is evaluated. However, ethical considerations 
do not allow for all patients to be treated solely with omega-3 
fatty acids or placebo over a period of 36 weeks. In cases of severe 
or treatment resistant depression, additional pharmacological 
therapies might be indicated. In a recent survey, 40% of 85,000 
depressed adolescents received AD medication during the 
course of their illness (96). This number appears relatively high 
given the major concern of increased suicidal ideations in the 
first weeks of treatment, which has been linked to the intake 
of ADs in minors (97, 98). In 2004, the advisory board of the 
Food and Drug Administration (FDA) decided to issue a black 
box warning indicating an increased risk of suicidal ideation in 
children receiving AD medication, especially SSRIs. Although 
further meta-analyses debated the increase of suicidal ideation 
after use of these drugs (99), it has contributed to a lot of 
insecurity in affected individuals and their families, as well as in 
the professional community (100).
When we designed the Omega-3 pMDD study, we evaluated 
several possible study designs. If we had decided to do a pure 
augmentation trial, the likelihood to lose those families opposed 
to AD medication (quite common in pediatric populations) would 
have been large. If we had decided to do a pure monotherapy 
omega-3 PUFAs RCT, we were concerned that clinicians would 
only refer less severe cases raising the risk of a ceiling effect due 
to the natural recovery rates of less severely depressed patients. 
Furthermore, omega-3 fatty acids seem to have better efficacy in 
severely depressed patients (23), potentially because more severe 
states of depression may be associated with stronger inflammatory 
processes. Both options were therefore considered less favorable 
to investigate the primary aim that omega-3 PUFAs have AD 
properties in moderately to severely depressed children and 
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adolescents. For all these reasons, we decided that concomitant 
treatment with AD medication is permitted to not compromise 
the representativeness of the sample and to ensure that patients 
receive the optimal therapy for their disorder. Our design will 
allow us to directly compare the effects of omega-3 fatty acids as 
a monotherapy as well as adjunct to other AD drugs. In addition, 
statistical methods including multiple imputations in those who 
are put on ADs will be employed to control for the effects of AD 
medications on the trials’ results. Without controlling for AD 
use, we would run the risk to compare omega-3 fatty acids with 
ADs instead of placebo. In the proposed additional intention-to-
treat analysis, we will consider the start of AD medication as a 
dropout criterion and impute the consecutive assessment time 
points of the main outcome measurements based on the values 
of those subjects that are not put on an AD. By considering the 
beginning of an AD as a treatment failure, we minimize the risk 
to mask a positive effect of omega-3 fatty acid supplementation 
by starting ADs more frequently or earlier in the placebo arm 
than in the omega-3 fatty acid arm. With this unique und novel 
way of analyzing the primary outcome data, the omega-3-pMDD 
trial aims to answer a wide range of questions regarding the 
treatment with omega-3 fatty acids, such as their efficacy and 
safety, the influence of omega-3 fatty acid supplementation on 
cognitive deficits associated with depression, and the emergence 
of putative biomarkers for omega-3 fatty acid treatment with and 
without the confounding effects of ADs.
METHODS AND ANAlySIS
Study Overview
The Omega-3-pMDD study is a Swiss multicenter, randomized, 
double blind, placebo controlled clinical trial, enrolling a 
sample of 220 individuals aged 8 to 17 years who have a present 
primary diagnosis of a major depressive disorder of at least 
moderate symptom severity. The study design incorporates a 
7- to 10-day lead in phase and a 36-week double blind placebo-
controlled treatment phase. The study was approved by the local 
ethics committees and the regulatory affairs and is registered 
at ClinicalTrials.gov protocol No NCT03167307. The primary 
outcome is changes in the Children’s Depression Rating Scale 
(CDRS-R) total score (101, 102). The categorical co-primary 
outcome includes response rates at 6 weeks and remission rates at 
12 and 36 weeks, and rates of recovery defined by the absence of 
major depression for > 4 months at 36 weeks. Secondary outcome 
measures are a variety of psychopathological, neuropsychological, 
and biological measures, including questionnaires, cognitive 
testing, and biological markers. In addition, potential response 
predictors are assessed, such as inflammatory mediators in 
serum, red blood cell acids, and bioactive lipid mediators.
Interventions
Intervention Group
The active treatment consists of a daily dose of 1,000 mg 
EPA/500 mg DHA in the over 13 years old. Meta-analyses in 
adults have shown that only drugs containing an EPA content 
over 60% are effective in the treatment of depressive disorders 
(24). Furthermore, according to the meta-analysis conducted 
by Grosso and colleagues (103), the optimal daily dose of 
omega-3 fatty acids is about 1.8 g, which is very close to the 1.5 
g administered in the current trial. In children under 13 years 
old, half the dose is administered resulting in 500-mg EPA/250 
mg DHA per day, which is a similar daily dose to the one 
used in the trial of prepubertal children conducted by Nemets 
and colleagues (33).
Control Group
The control group receives placebo capsules containing mostly 
medium chain triglycerides (MCT), because they do not contain 
any unsaturated fatty acids, and in these small quantities, they 
do not have any pharmacological effect. A major concern is that 
omega-3 fatty acids capsules could be “unblinded” because of 
the fishy taste. Therefore, a small amount of fish oil is added to 
the placebo capsules to mimic the taste, preventing guessing of 
the treatment arm (104). Capsules are especially manufactured 
so that they can easily be swallowed by children. In addition, 
they will contain natural orange flavor for a pleasant odor when 
opening the bottle and so optimizing compliance.
Concomitant Interventions
The background treatment across both groups is standardized 
based on the evidence and consensus-based German S3 
Guidelines for the treatment of depression in children and 
adolescents (105). The core element is based on the cognitive 
behavioral therapy (CBT) method that includes individual CBT 
as well as psycho-educational family sessions. All participant 
sites are trained accordingly. In severe or treatment resistant 
cases of depression, the prescription of AD drugs might be 
indicated by experienced senior clinicians of the participating 
centers. Medicated patients can still participate in the trial. 
However, the start time and dose of the AD medication are 
recorded and are taken into account in the statistical analyses, as 
described further below.
Participants and Recruitment Methods
Participant Eligibility
Table 1 displays the inclusion and exclusion criteria used in the 
trial and their corresponding rationale. Given that omega-3 fatty 
acids were shown to be mainly efficient in clinically diagnosed 
patients (23), diagnosis criteria for major depressive disorder are 
carefully assessed to ensure that all patients fulfill the diagnosis 
of a major depressive disorder (MDD) according to DSM-IV. 
In addition, the severity of the symptoms needs to be of at least 
moderate severity, as measured by a revised Children’s Depression 
Rating Scale (CDRS-R) total score of ≥40. Patients with the 
primary diagnosis of schizophrenia, bipolar affective disorder, 
substance use dependency, pervasive developmental disorders 
(autism), neurological conditions or the diagnosis of an eating 
disorder within the last 6 months are excluded from the trial. 
Other comorbid disorders, such as attention deficit disorders, 
anxiety disorder or conduct disorders, are not considered to be a 
reason for exclusion of the trial, but are recorded as pre-specified 
comorbidities to allow the identification of clinical subgroups 
Frontiers in Psychiatry | www.frontiersin.org November 2019 | Volume 10 | Article 863
The Omega-3-pMDD Trial: Rationale and DesignHäberling et al.
6
which might differ in their treatment response. Furthermore, 
routine laboratory blood testing is performed before the 
intervention time to ensure the well-being of the patients and to 
detect any medical problems. Given the ongoing debate whether 
omega-3 fatty intake might increase bleeding time (106), 
coagulation parameters will be assessed and in case of clinically 
significant values patients will not be able to take part in the trial.
Recruitment
Children and adolescents meeting criteria for clinical depression 
are recruited from mental health in- and outpatient services in 
the German speaking part of Switzerland. In all participating 
centers, the study team performs annual workshops introducing 
the study. Patients and their families are only contacted 
directly by the investigators once clinicians have explored their 
willingness to be informed about the study. Thereafter, the first 
visit is scheduled during which patients and their families are 
informed about the nature and course of the study, and the 
study information and informed consent are handed out. The 
study team answers all questions, and the families are advised 
not to sign immediately but to think it over for at least another 
day before enrolling. Once the patients and their legal guardian 
have signed, the consent form appointments for the first week 
are scheduled.
Research assessments are carried out by the central 
study team, which will visit patients and their families in 
the participating centers or at their homes. All research 
psychologists will complete training courses for the clinical 
interviews and the cognitive tests prior to visiting patients. 
Scoring of clinical interviews will be tested using video footage 
of patients being assessed. Furthermore, all new staff members 
will be directly observed in their first research assessments, and 
symptoms will be scored simultaneously by other researchers 
until a good agreement is reached. To ensure the reliability of 
the data and to detect any inconsistencies in assessments, weekly 
research meetings will be held, during which symptom ratings 
and fulfillment of diagnostic criteria are discussed with senior 
clinicians (GB, SW).
Stratification and Randomization
The data are stratified by sex (male, female), age group (≥ 13 
years old, < 13 years old), center, and whether the patient belongs 
to an in- or outpatient unit. In addition, the value of the high 
sensitive C-reactive protein (hsCRP) forms another stratification 
parameter (low < 1 mg/L; average 1.0–3.0 mg/L; high > 3.0 
mg/L). Previous studies in adults (107, 108) and adolescents 
(109) have shown serum hsCRP to be an independent risk 
factor in depressive disorders, highlighting the role of low grade 
inflammation in the pathogenesis of mood disorders. Given the 
anti-inflammatory mechanisms of omega-3 fatty acids, a balanced 
allocation of patients with and without low-grade inflammation 
in the treatment arms are warranted. Randomization is carried 
out using the in-built functions of the clinical trial software 
SecuTrial®. SecuTrial® assigns the patient to the subgroup which 
leads to least imbalance within all strata. The software then 
provides a randomization number from a list implemented 
previously by a data administrator not otherwise involved in the 
TABlE 1 | Inclusion and exclusion criteria Omega-3-pMDD trial.
Inclusion Criteria Rationale
Male or female in- or outpatients of a participating center Standard treatment of depression according to S3 guidelines
Youth aged 8 to 17 years Matches developmental sensitivity of treatment and measures
Primary diagnosis of major depressive disorder with depressive symptoms of at least moderate 
severity (CDRS-R total score of ≥40)
Clinically significant and diagnosed MDD
No clinically significant laboratory findings. Guarantees safety and proper treatment
Able to swallow the study medication without difficulty Guarantees compliance
Exclusion Criteria Rationale
Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy Guarantees safety of patients (e.g. fish allergy)
Regular omega-3 supplementation within the last 6 months Potential confounding factor
Lack of safe contraception; women who are pregnant, breast feeding, or have the intention to 
become pregnant during the course of the study
Ethical considerations
Pre-existing neurological (such as brain tumor, temporal lobe epilepsy, HIV encephalopathy) or 
medical conditions likely to be responsible for the depressive symptoms
May require additional or different treatment
Known or suspected non-compliance Guarantees compliance
Inability to follow the procedures of the study, e.g. due to language problems, psychological 
disorders, dementia, etc. of the participant
Cannot complete study assessment
Participation in another study with investigational drug within the 30 days preceding and during the 
present study
Potentially confounding factor
Previous enrolment into the current study Potentially confounding factor
Enrolment of the investigator, his/her family members, employees, and other dependent persons Ethical considerations
Substance dependency (ICD-10 F1x.2) within the last 6 months (but not misuse) May require different or additional treatment
Lifetime diagnosis of schizophrenia and related disorders (ICD-10 F20-F25) May require different or additional treatment
Lifetime diagnosis of bipolar affective disorder in the K-SADS-PL (ICD-10 F30, F31) May require different or additional treatment
Current eating disorders within the last 6 months (ICD-10 F50.0 and F50.2), May require different or additional treatment, compliance risk
Mental retardation (ICD-10 F70-73) May require different or additional treatment, difficulties following 
research assessments
Pervasive development disorder (ICD-10 F84.x) May require different or additional treatment
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study. Given that not always the next randomization number is 
selected by the computer, the study team is unable to guess what 
the next number will be. The research psychologist hands out the 
correct trial medication, which are stored in identical bottles and 
with the number as only identification.
Assessments
Primary Outcome Assessments/Parameters
The primary outcome is change in the total score of the Children’s 
Depression Rating Scale- revised (CDRS-R), measured on a 
continuous scale. Co-primary categorical outcomes are response 
rate to treatment at week 6, remission rate at weeks 12, 24, and 
36, and recovery rate at 36 weeks. The CDRS-R is a 17-item scale 
and quantifies childhood (102) and adolescent (110) depressive 
symptoms with a total score of ≥40 indicating moderate to severe 
depression and has been extensively used in research (111). The 
scale is also evaluated in German (112). Response is defined 
as a 30% decrease in the total CDRS-R scores (113), whereas a 
score ≤28 is being used to define remission. Recovery is defined 
as the absence of the diagnosis of MDD for > 4 months, and is 
established with the semi-structured interview Kiddie Schedule 
for Affective Disorders and Schizophrenia — Present and Lifetime 
Version (K-SADS-PL) (114). The K-SADS-PL is a diagnostic 
interview designed to assess current and past DSM-IV diagnoses 
in children and adolescents, by interviewing the parent(s) and 
child. The section for diagnosing the presence of a current 
major depressive disorder confirms the presence of a MDD at 
baseline and determines recovery status of a study participant at 
each assessment time point. In addition, the K-SADS-PL is also 
used to assess comorbid disorders and to ensure inclusion and 
exclusion criteria are met.
Secondary Outcome Assessments/Parameters
Secondary outcome assessments consist of a variety of 
questionnaires, rating scales, and neuropsychological tests, as 
summarized in Table 2. Depression severity is additionally 
assessed through a self-report questionnaire, the Depression 
Inventory for Children and Adolescents (DIKJ) (115). Suicidal 
ideation is assessed using the Suicidal Ideation Questionnaire 
(118) with adolescents over 13 years also filling in the Beck’s 
hopelessness Scale (116). Anxiety levels are assessed through 
the Beck’s anxiety inventory (117), and emotional instability as 
well as other borderline traits are rated by parents and patients 
over 13 years of age using the German versions of the IES-27 
(124). Stress is monitored with the Perceived Stress Scale (PSS) 
(121), while the Connor Davidson Resilience Scale (120) is 
used to estimate resilience. Sleep quality is assessed using the 
Insomnia Severity Index (119). Parents and patients rate quality 
of life with the Kidscreen (132) with parents and patients over 
the age of 11 years also rating behavioral problems using the 
Strength and Difficulty Questionnaire (SDQ) (123). In addition, 
childhood maltreatment is assessed with the Childhood Trauma 
Questionnaire (CTQ) (138) while victimization in the school 
environment is assessed with the Olweus Bullying Questionnaire 
(OBQ) (139).
Clinician-Rated Scales
In addition to self- and parent-rated instruments, clinicians 
treating the patients are asked to fill in three short rating scales. 
Clinicians rate symptom severity and global improvement on 
the Clinical Global impression scale (CGI-S/I) (125) and global 
functioning on the Children’s Global Assessment of functioning 
(CGAS) scale (126). In addition, behavior, impairment, symptom 
severity, and social functioning are scored on the Health of the 
Nation Outcome Scale for Children and Adolescents (HoNOSCA) 
(127). Furthermore, clinicians indicate how many minutes they 
spent treating the patient between study assessments.
Cognitive Assessments
The level of cognitive functioning is assessed using a variety 
of standardized neuropsychological tests. Different episodic 
memory parameters are assessed with the Verbal Memory 
Learning Test (VMLT) (129), while working memory is 
tested with the Digit Span Forward and Backward of the 
Wechsler Intelligence Test for Children (WISC IV) (130). The 
Regensburger Word Fluency Test measures verbal fluency 
as a function of divergent thinking (132). The ability to shift 
attention and inhibit responses is assessed with the Shifting 
Visual Attention Test of the computerized Amsterdam 
Neuropsychological Test battery (131). Included in the same 
test battery is also the Identifying Facial Emotions test which 
assesses the ability of a subject to recognize emotions displayed 
in faces. In addition, executive functioning is assessed with the 
Behavior Rating Inventory of Executive Function (BRIEF) (128, 
140), in which parents and patients over the age of 11 years rate 
the level of impairment of executive functioning in daily life. 
And finally, intellectual abilities are assessed with the Reynolds 
Intellectual Assessment Scale (RIAS) (133).
Biological Assessments
Blood is drawn three times during the course of the study, at 
baseline, 12 weeks, and at 36 weeks, respectively. At baseline, 
routine laboratory parameters are assessed to ensure that the 
patients are healthy and do not need any immediate medical 
attention. The remaining blood is stored for PUFAs (omega-
3, -6, and -9 and trans fatty acids), bioactive lipids (e.g., 
eicosanoids, hydroxy metabolites, E-series resolvins), immune 
parameters (including but not restricted to interferon-γ, IL-1α, 
IL-1RA, IL-5, Il-6, IL-10, IL12p40, IL-15, IL-18, and TNF-α, 
as well as leptin and adiponetin), and for the tissue repository. 
Since multiple studies are currently investigating biomarkers 
in MDD, serum, lymphocytes, erythrocyte, platelets, and 
DNA will be stored after the end of the study to measure 
potential novel biomarkers. Genetic and epigenetic markers of 
interest (e.g. FADS haplotypes) include but are not restricted 
to genes relevant for bioactive lipid metabolism. In addition 
to the blood sample, patients are asked to provide 3 cm of 
hair in order to assess the steroid profile, including cortisol, 
testosterone, progesterone, dehydroepiandrosterone, and 
estradiol levels at 6 weeks and 9 months. Furthermore, saliva 
(cortisol, melatonin) and urine (drug screen, F2 isoprostane 
as a marker of lipid oxidation) are sampled. Biological samples 
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are stored in a biobank for use in future research if patients 
and their parents agree to sign an additional consent form.
Compliance, Safety, and Other Measures
Compliance is monitored with the Medication Adherence Reporting 
Scale (MARS-D) (135). In addition, returned capsules are counted 
at each study visit. Potential side effects are assessed with a modified 
version of the Antidepressant Side Effect Checklist (ASEC) at each 
visit (134). The daily nutritional intake of omega-3 fatty acid is 
estimated with an adapted version of the Omega-3 Food Frequency 
Questionnaire (136), three times during the course of the trial.
Study Schedule
A flowchart of the study schedule is depicted in Figure 1. 
After the consent process, patients and their families undergo 
a screening interview in order to assess inclusion criteria, such 
as the diagnosis and severity of the depressive disorder and 
exclusion criteria, such as comorbidities that might prevent 
participation. Sociodemographic data and information about 
medical and family history and current medication use is also 
collected. If a patient is considered eligible for the trial, he or 
she enters the 7 to 10 days single blinded placebo lead-in phase. 
All patients receive placebo capsules for at least 7 days prior to 
TABlE 2 | Outcome measures Omega-3-pMDD trial.
Primary outcome measures Scale Examiner
Depression severity Children’s Depression Rating Scale (102) Interview with parents and patients
Diagnosis of MDD K-SADS-PL(114) Interview with parents and patients
Secondary outcome measures (part A)
Depression severity Children’s Depression Inventory (DIKJ) (115) Self-report
Hopelessness Beck Hopelessness Scale (116) Self-report
Anxiety Beck Anxiety Inventory (BAI) (117) Self-report
Suicidality Suicidal ideation questionnaire (SIQ-JR) (118) Self-report
Sleep Insomnia Severity Index (ISI) (119) Self-report
Resilience Connor-Davidson Resilience Scale (120) Self-report
Secondary outcome measures (part B)
Stress Perceived Stress Scale (PSS-10) (121) Self-report
Quality of life KIDScreen-Cat (122) Self- and parent report
Behavior Strength- and difficulties Questionnaire (SDQ) (123) Self- and parent report
Emotional Instability IES-27 (124) Self- and parent report
Clinician rated variables
Global impression Clinical Global Impression Scale (125) Clinician
Functioning Children Global Assessment Scale (126) Clinician
General health and social functioning HoNOSCA (127) Clinician
attrition Attrition checklist Clinician
Cognitive outcome variables
Executive functions BRIEF (128) Self- and parent report
Memory VLMT (129) Researcher
Working memory WISC-IV (130) Researcher
Attention ANT (131) Researcher
Emotion recognition ANT (131) Researcher
Verbal fluidity RWFT (132) Researcher
Intelligence Reynolds Intellectual Assessment Scales (133) Researcher
Biological outcome measures
Clinical blood Electrolytes, red and white blood tests (e.g. hemoglobin, 
hematocrit, leucocytes), thyroid function test, liver, and kidney 
function test, thrombocytes, thromboplastin (blood coagulation)
Study nurse (processed and analyzed in a certified 
clinical laboratory)
Blood Omega-3, 6,9 fatty acid levels and bioactive lipids (e.g. 
eicosanoids)
Study nurse (centrifuged immediately after blood 
taking; further processing in a specialized research 
laboratory of the children’s hospital Zürich)
Urine Drug screen, F2 isoprostane Study nurse
Saliva Cortisol Study nurse
hair Steroid profile Study nurse
Other measures
Side effects ASEC (134) Self-report
Compliance MARS-D (135) Self-report
Compliance Pill count Researcher
Omega-3 intake Omega-3 Food Frequency Questionnaire (136) Self-report
Puberty status Tanner questionnaire (137) Self-report/parents for younger children
Childhood maltreatment Childhood Trauma Questionnaire (138) Self-report
Bullying/victimization Olweus Bully/Victim Questionnaire (139) Self-report
Sociodemographic data Questionnaire Interview, clinic information system
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randomization in order to assess any difficulties in swallowing the 
medication and measure compliance. Furthermore, the lead-in 
phase allows the identification of fast placebo responders. The 
baseline visit takes place at the end of the placebo lead-in phase, 
during which the CDRS and the subscale depressive disorder of 
the K-SADS-PL will be administered for a second time. If the 
patient still fulfills the diagnosis of a major depressive disorder 
with at least moderate severity, and no other exclusion criteria 
have emerged, the patient is randomized. Four follow-up 
assessments at 6, 12, 24, and 36 weeks are performed, consisting 
mainly out of the same measurements taken during the lead-in 
phase. Only four follow-up measurements are scheduled given 
that the number of research assessments has been identified as 
a predictor for placebo response (141, 142). The timing of the 
assessments was based on the design of the “Treatment for 
Adolescents with Depression” study (143), allowing us to make 
direct comparisons of illness trajectories between the trials. 
Intelligence is assessed only once at the 6-week appointment, 
and hair sample are taken at the 6-week appointment and at 
the end of the trial. Unused study drugs are counted at each 
appointment with compliance rates below 60% resulting in the 
discontinuation of the trial.
Participants’ Compensation
There is only a small compensation for participation with patients 
receiving a voucher of about 20 CHF three times during the 
course of the study. Additional travelling costs (i.e., train fares) 
are recompensed.
Data Management and Analytic Approach
Data Acquisition and Security
All data collected for the Omega-3-pMDD study are entered 
into electronic case report forms hosted on a secure server of 
the Clinical Trials Centre of the University Hospital of Zurich. 
Each participant is assigned a study ID at enrolment, which is 
subsequently used to enter data into the clinical trial software 
SecuTrial® (www.secutrial.com). All data that are not entered 
directly by the patients or their parents are entered twice by two 
different investigators with another investigator checking the 
consistency of the double data entry and resolving all conflict. 
In addition, data quality is ensured through regular on-site 
monitoring by the Clinical Trials Centre of the University 
Hospital of Zürich. Data security, on the other hand, is guaranteed 
by encrypted communication and stringent firewall settings. 
Automated backups are made every 24 h to guarantee that no data 
are lost. Confidentiality of the data will be granted at all times.
Sample Size
Our power calculation was based on the available meta-analysis 
at the time of grant submission. The available meta-analyses 
provided an expected SMD of omega-3 PUFAs between 0.28 and 
0.56 mainly based on adult omega-3 intervention trials (22, 24–26, FIGuRE 1 | Flowchart study schedule Omega-3-pMDD trial.
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69). However, at this time point no studies in pediatric MDD were 
published, except one very small (n = 20) pilot study in childhood 
depression showing a large effect size (SMD = 1.4) (33). Because 
of the confounding factor of concomitant AD therapy and an 
expected high placebo response in pediatric populations, we 
introduced a range of measures, such as a placebo-lead in phase 
and conservative expected difference effect size between active 
and placebo. We used the following assumptions for our power 
calculation: Cohen’s d as effect size, calculated as difference 
between means in the two treatment groups divided by their 
pooled standard deviation, was considered to be 0.4, and with a 
significance level alpha of 5% and a power of 80%, 100 patients 
per group would be necessary to detect the clinically relevant 
difference with a two-sample, two-sided t-test, resulting in 200 
patients in total. With an anticipated dropout rate of 10% within 
the first six weeks after randomization (the time point of the 
first follow up assessment), the number of patients for this study 
would be 220. The study is sufficiently powered to address also the 
co-primary endpoint according to the following considerations: 
the proportion of patients with clinically relevant improvement in 
the group of patients receiving omega-3 is P(omega-3) = 0.60, and 
the corresponding proportion of patients in the placebo group is 
P(placebo) = 0.40. With a significance level of 0.05 for a two-tailed 
chi-squared test and an anticipated power of 80%, 97 patients per 
treatment group would be needed. With an anticipated dropout 
rate of 10%, 220 patients would be sufficient to address this 
clinically relevant endpoint.
Based on the preliminary analysis of the baseline data of 
the on-going trial, 2/3 of the patients are AD free at the time of 
randomization, with most of them still being AD free after the 
first follow-up. A sample size of n = 74 per treatment arm in 
this subgroup of AD-free participants will enable us to detect a 
moderate SMD of 0.54 using a two-group t test for the CRSR-R 
total score with a 0.05 two-sided significance level and a 90% 
power. The entire ITT sample (also encompassing the third with 
pre-existing AD treatment) will even enable us to detect small 
effect sizes between active/placebo. Meta-analyses of omega- 3 
PUFA supplementation in depression suggest that omega-3 PUFA 
augmentation trials show an even larger effect size compared to 
omega-3 monotherapy RCTs (31, 144, 145), in particular if EPA 
rich formulations or pure EPA is considered (146).
Statistical Analysis
Descriptive statistics include mean and standard deviation for 
continuous variables, as well as number and percentages of total 
for categorical variables. Ordinal scaled variables will be reported 
as median and interquartile range. Descriptive statistics will be 
reported within treatment groups.
Primary analysis is performed based on the intention to 
treat (ITT) principle, i.e. including all randomized patients. 
For the continuous primary outcome (total CDRS-R score), 
we will apply a linear random intercept regression model. For 
the co-primary endpoint, i.e., the binary outcome measure for 
treatment response, we will apply a logistic regression model, 
and treatment group as independent variable will be used. 
Results will be presented as effect estimates — beta-coefficients 
or odds ratios — with 95% confidence intervals for primary and 
co-primary endpoints, respectively.
However, the analysis of treatment efficacy of the omega-3 
fatty acids needs to address that some study participants already 
receive ADs prior to study inclusion or will be put on ADs in 
the due course of the study. The additional use of ADs might 
not be uniformly distributed between the two treatment arms, 
which might introduce biased results if not accounted for. To 
account for this major confounding factor, we propose to use two 
different analytic approaches. (1) We will perform an additional 
ITT analysis of the primary and secondary outcomes defining the 
beginning of an AD as a treatment failure and include treatment 
failure/additional use of AD as time-dependent covariate in the 
random effects model. (2) Using 20-fold multiple imputation, 
depression scores that a patient would have had without AD 
prescriptions are estimated, based on consecutive data of subjects 
without AD, and on earlier observations in the same subjects. 
To address that the missingness generating mechanism is 
considered to be “missing not at random” (MNAR), the “drawn 
indicator method” proposed by Jolani et al. (147) will be applied. 
A subsequent sensitivity analysis of the results will reveal the 
dependence of the results on specific assumptions in the two 
different analytic approaches.
A pre-specified subgroup analysis will address whether there 
is a differential treatment effect between patients with or without 
the pre-specified variable (e.g. AD therapy at baseline). If there is 
evidence for an interaction (as quantified with the p-value of the 
corresponding interaction test), the treatment effect will also be 
reported in those subgroups.
Furthermore, we’ll run following analyses to investigate the 
impact of AD use based on a priori working hypotheses: Firstly, 
we will test differences in novel AD prescriptions between 
the treatment groups by means of the two proportions z-Test 
using the ITT sample (assuming that ADs are more frequently 
prescribed in the placebo arm). We will also calculate retention 
rates between the two groups by means of the two proportions 
z-Test prior of “dropping out” those subjects put on ADs 
(assuming that the retention rate is longer in the active compared 
to the placebo arm).
Further analyses on primary and secondary outcome 
measures will be run as detailed in the study protocol, which is 
available on the clinical.trials.gov website.
Safety Considerations
Omega-3 fatty acids are usually well-tolerated, but according to 
a recent meta-analysis by Chang et al. (148), they might elicit 
mild adverse effects such as gastrointestinal symptoms in some 
patients. In a meta-analysis including 148 omega-3 fatty acid 
studies with dosage up to 6 g per day, 6.6% of the active group 
relative to 4.3% in the placebo group reported gastrointestinal 
complaints. Only one study reported an increase in bleeding 
time (64). Thus, any medical conditions experienced during the 
trial are recorded. In addition, patients fill in the ASEC at each 
visit to measure other putative side effects. No doses changes of 
active/placebo are permitted during the trial, but patients and 
their families are informed of the voluntary nature of the study 
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and that consent can be rescinded anytime. While no serious 
side effects are expected due to omega-3 fatty acids intake, the 
current patient population warrants for a tight safety control 
due to the risk of suicide. Therefore, suicidal tendencies will be 
closely monitored by the study team by asking directly about 
suicidal ideations during the clinical interviews in addition to the 
administration of the Suicidal Ideation Questionnaire (SIQ-Jr). 
Furthermore, a data monitoring committee (DMC) is set up 
consisting of an expert in child and adolescent psychiatry, an 
expert in ethical considerations, and an expert in biostatistics. All 
members have access to the unblinded data due to permissions 
associated with their study function in the database SecuTrial. 
In case of a serious adverse event, the members of the DMC 
are automatically notified through an inbuilt function of the 
software in order for them to continuously monitor the safety of 
the patients. Furthermore, after 60 enrolled patients, an interims 
analysis on the safety of the treatment is was performed by a 
member of the DMC.
Publication and Dissemination
The main outcome of the trial is published irrespective of 
the results. A publications committee establishes publication 
guidelines and coordinates the publication of secondary outcome 
measures, also giving recommendations to the timing of different 
abstracts, reviewing all publications for their appropriateness and 
scientific merit. No later than five years after closure of the data 
base, a completely de-identified data set will be provided for 
sharing purposes.
DISCuSSION
This paper describes the design and methodology for a clinical 
trial evaluating the efficacy and safety of omega-3 fatty acids as a 
treatment for pediatric depression. It is paramount for children 
and adolescents suffering from mental problems to receive 
appropriate treatment. However, affected families often don’t 
seek help because of the stigma associated with mental illness 
and psychiatric treatments (149). Being open to novel treatments 
such as omega-3 fatty acids that are closely linked to lifestyle, 
food, and general well-being may indirectly encourage affected 
families to seek help sooner. If omega-3 fatty acids prove to 
be beneficial, they might serve as a benign well-accepted first 
step in a comprehensive treatment plan. On the other hand, 
if omega-3 fatty acids prove to be ineffective, the results are as 
important given the risks associated with delaying other effective 
treatments due to an unjustified supplementation of omega-3 
fatty acids. Therefore, this well-designed large-scale clinical trial 
will provide important information on the optimal management 
and treatment of pediatric depression.
In our study design, we permit concomitant AD medication, 
to ensure the representativeness of our sample and the inclusion 
of more severely depressed patients. However, we will study 
the confounding effects by running subgroup analyses and 
statistically controlling for use of AD drugs. We believe that the 
abovementioned measures and the large sample size will allow us 
to address both the question if omega-3 fatty acids are effective 
as a first-line treatment, as well as to address the question of 
augmenting a pre-existing AD treatment with omega-3 PUFAs 
will further improve treatment outcomes.
The long study duration of 36 weeks allows studying the trajectory 
of a variety of psychopathological and cognitive symptoms associated 
with depression. Patients fill in a full range of questionnaires ranging 
from anxiety and emotional instability to sleep disturbances1 to 
dietary omega-3 fatty intake. This allows the characterization of 
symptoms that are affected by omega-3 fatty acid intake and the 
establishment of subgroups of patients profiting the most from the 
treatment. Pre-treatment blood levels of omega-3, 6, and 9 fatty acids 
are used to predict treatment response, and a variety of biological 
parameters are assessed in order to enhance our understanding of 
the biological mechanism associated with depression and the effects 
of omega-3 fatty acids on the brain. This is especially important 
given the on-going brain development in minors and the severe 
impacts of pediatric depression on brain structure and function 
(150). The establishment of a biobank creates a database of a highly 
unique sample that allows for further studying of the underlying 
biological mechanisms of pediatric depression. Therefore, this trial 
will advance our understanding of the pathogenesis of depression in 
minors and will provide a valuable contribution to the best treatment 
options of this severely affected patient group.
THE OMEGA-3 STuDy TEAM 
The Omega-3 Study Team contributed with implementation of 
the design with following roles: Sponsor-investigator of the trial is 
GB (Department of Child and Adolescent Psychiatry, University 
Hospital of Psychiatry, University of Zurich, Neumünsterallee 
9, 8032 Zurich, Switzerland; gregor.berger@puk.zh.ch; +41 
43 499 2626). Chief investigators are SW and KS. IH is study 
coordinator. Principal investigators and research psychologist 
from the clinical sites are as follows: Principal Investigator 
Zurich: SW; Research psychologists: Noemi Baumgartner, Sophie 
Emery, Mona Albermann, and Kristin Nalani (Department 
of Child and Adolescent Psychiatry, University Hospital of 
Zurich); Principal Investigator Basel: KS; Investigators and 
research psychologists: Oliver Pick, Alain Di Gallo, and Michael 
Strumberger (Department of Child and Adolescent Psychiatry, 
Psychiatric University Hospitals Basel); Principal Investigator 
Basel-Stadt: Brigitte Contin; Investigator: Stefan Müller (Child 
and Adolescent Psychiatric Services Baselland); Principal 
Investigator: Silke Bachmann; Investigators: Lars Wöckel, and 
Simone Heitzer (Clienia Littenheid); Principal Investigator: 
Bruno Rhiner; Investigators: Amir Yamini (Child and Adolescent 
Psychiatric Services Thurgau); Principal Investigator: Suzanne 
Erb; Investigators: Michael Schmid (Child and Adolescent 
Psychiatric Services St. Gallen); Principal Investigator: Ulrich 
Müller-Knapp; Investigator: Ioannis Christodoulakis (Klinik 
Sonnenhof). UH and Burkhardt Seifert (retired) are statistical 
consultants. Renate Drechsler is head of the neuropsychology 
1An add-on study under supervision of Prof. Christian Cajochen and Prof. Klaus 
Schmeck will investigate the effects of omega-3 fatty acids supplementation on 
sleep and physical activity in a subgroup of the depressed patients.
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department and Edna Grünblatt head of the department for 
translational molecular psychiatry (Department of Child and 
Adolescent Psychiatry, University Hospital of Zurich). Martin 
Hersberger is head of the division of Clinical Chemistry and 
Biochemistry at the University Children’s Hospital Zürichand his 
PhD student Ivan Hartling of the division of Clinical Chemistry 
and Biochemistry who will analyze the bioactive lipids; Romuald 
Brunner (University of Heidelberg), Jürgen Drewe (University 
of Basel), and Julia Braun (Epidemiology, Biostatistics, and 
Prevention Institute, University of Zürich) are members of the 
Data Monitoring Committee. Jenny Peterson, Clinical Trials 
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